WINSTON-SALEM, N.C., March 4, 2014 (GLOBE NEWSWIRE) -- Tengion, Inc. (OTCQB:TNGN), a leader in regenerative medicine, today announced that John L. Miclot, President and Chief Executive Officer of Tengion, will present at the upcoming 26th Annual ROTH Conference on Monday, March 10, 2014, at 12:30 p.m. PDT in Dana Point, CA.
A live audio webcast of the presentation can be accessed at http://wsw.com/webcast/roth28/TNGN or under "Calendar of Events" in the Investors & News section of the Company's website at www.tengion.com. A replay of the presentation will be available on Tengion's website for 90 days. Investors interested in listening to the live webcast should log on before the start time in order to download any software required.
Tengion, a clinical-stage regenerative medicine company, is focused on developing its Organ Regeneration Platform™ to harness the intrinsic regenerative pathways of the body to regenerate a range of native-like organs and tissues with the goal of delaying or eliminating the need for chronic disease therapies, organ transplantation, and the administration of anti-rejection medications. The Company is currently conducting Phase 1 clinical trials in Sweden and the U.S. for its Neo-Kidney Augment, which is intended to prevent or delay dialysis and transplantation by increasing renal function in patients with advanced chronic kidney disease. A Phase 1 trial for the Company's Neo-Urinary Conduit, an autologous implant that is intended to catalyze regeneration of native-like urinary tissue for bladder cancer patients requiring a urinary diversion following bladder removal, is ongoing.
CONTACT: Investor and Media Contact: Brian Davis firstname.lastname@example.org 336.201.0155Source:Tengion, Inc.